How to handle side effects of enfortumab vedotin + pembrolizumab

Wednesday, 5 June 2024 | Urogenital

Enfortumab vedotin (EV) plus pembrolizumab has recently been established as the new first-line treatment standard in advanced urothelial carcinoma. Clear guidance on how to manage the typical side effects of this regimen is necessary to allow for the successful use of this life-extending treatment in the individual patient.

To continue, please login or sign up first